|
|
|
| Investigation and analysis on the use of monosialotetrahexosylganglioside sodium in 764 inpatients |
| Su Yunxia1, Li Xiaoxue2, Wu Yingying1, Wang Yuehong1, Xu Xiaoxia3, Wang Xiang1 |
1 Pharmacy Department, the 72nd Army Group Hospital of PLA, Huzhou 313000, China;
2 Department of Pharmacy, Wannan Medical College, Wuhu 241000, China;
3 Department of Information, the 72nd Army Group Hospital of PLA, Huzhou 313000, China |
|
|
|
|
Abstract Objecive To understand the use of monosialotetrahexosylganglioside sodium in a hospital, and analyze its rationality, so as to provide reference for clinical safety and rational drug use. Methods The use of monosialotetrahexosylganglioside sodium in inpatients in a hospital from January to December 2018 was analyzed retrospectively, and the rationality was analyzed according to the drug instructions, relevant guidelines and consensus. Results The DUI and DDDC of monosialotetrahexosylganglioside sodium were 1.71 and 169.41 yuan per day respectively. Most of the visited departments were neurosurgery, intensive care and rehabilitation. In 764 patients, their rational rate of indication, irrational usage and dosage, the irrational rate of treatment course, the irrational rate of clinical combined drug use, and the incidence of adverse reactions was 27.2%, 94.5%, 76.4%, 6.9% and 1.2%, respectively. Conclusion There are unreasonable phenomena in the use of monosialotetrahexosylganglioside sodium, the unreasonable problems such as indication, dosage and course of treatment are more prominent, and there are hidden worries about the safety of drug use. The use of monosialotetrahexosylganglioside sodium should be further regulated.
|
|
Received: 27 October 2020
|
|
|
|
［1］孙超，乔欢．国内单唾液酸四己糖神经节苷脂钠注射液致不良反应23例文献分析［J］．淮海医药，2017，35(4)：460-462．
［2］医政医管局.国家卫生健康委办公厅关于做好辅助用药临床应用管理有关工作的通知）［EB/OL］.（2018-12-12）［2020-10-27］ http://www.nhc.gov.cn/yzygj/s7659/201812/bc0259007f1a4cf38cb5d0352470e33e.shtml．
［3］医政医管局.关于印发第一批国家重点监控合理用药药品目录（化药及生物制品）的通知［EB/OL］.(2019-07-01)［2020-10-27］ http://www.nhc.gov.cn/yzygj/s7659/201907/d356ce8a4ba1461ca66c544724dffc 5e. shtml.
［4］南家林，王小藕．某院单唾液酸四己糖神经节苷脂钠注射液使用情况调查分析［J］．中国药物评价，2017，34(4)：281-284．
［5］崔海珍，于倩，李忻．6455例单唾液酸四己糖神经节苷脂钠合理用药评价［J］．中国药物应用与监测，2018，15(4)：236-238．
［6］陈沈珏，刘丽华，何鑫，等．某院1435例单唾液酸四己糖神经节苷脂钠应用合理性分析［J］．药物流行病学杂志，2019，28(3)：181-185．
［7］马冰洁，陈超，苍爱军．神经外科术后患者应用单唾液酸四己糖神经节苷脂的合理性分析和不良反应研究［J］．实用药物与临床，2020，23(3)：272-275．
［8］邱希颖，林惠娥，郑茹萍．解放军第一八〇医院2014—2016年神经营养类辅助用药的应用分析［J］．临床药物治疗杂志，2017，15(10)：40-45．
［9］中国神经科学学会神经损伤与修复分会．脑损伤神经功能损害与修复专家共识［J］．中华神经创伤外科电子杂志，2016，2(2)：100-104．
［10］CARNEY N, TOTTEN A M, O′REILLY C et al. Guidelines for the management of severe traumatic brain injury：fourth edition［J］. Neurosurgery，2017, 80(1):6-15． ［11］中华预防医学会脊柱疾病预防与控制专业委员会脊柱脊髓损伤疾病预防与控制学组，中国康复医学会脊柱脊髓专业委员会基础研究学组．急性脊柱脊髓损伤围术期管理临床指南［J］．中华创伤杂志，2019，35(7)：577-587．
［12］GEISLER F H, DORSEY F C, COLEMAN W P.Recovery of motor function after spinalcord injury:A randomized, placebo-controlled trial with GM-1 ganglioside［J］. N Engl J Med，1991,324(26):1829-1838．
［13］中国医师协会骨科医师分会,中国医师协会骨科医师分会《成人急性下颈段脊柱脊髓损伤循证临床诊疗指南》编辑委员会.中国医师协会骨科医师分会骨科循证临床诊疗指南:成人急性下颈段脊柱脊髓损伤循证临床诊疗指南［J］.中华外科杂志,2018,56(1):5-9.
［14］中国医师协会骨科医师分会,中国医师协会骨科医师分会《成人急性胸腰段脊柱脊髓损伤循证临床诊疗指南》编辑委员会.中国医师协会骨科医师分会骨科循证临床诊疗指南:成人急性胸腰段脊柱脊髓损伤循证临床诊疗指南［J］.中华外科杂志,2019,57(3):161-165.
［15］NICE GIDELINE. Spinal Injury: Assessment and Initial Management［EB/OL］.https://www.nice.org.uk/guidance/ng41/resources/spinal-injury-assessment-and-initial-management-pdf-1837447790533/2021-1-29.
［16］中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组．中国脑出血诊治指南(2014)［J］．中华神经科杂志，2015，48(6)：435-444．
［17］中华医学会神经外科学分会，中国医师协会急诊医师分会，国家卫生和计划生育委员会脑卒中筛查与防治工程委员会．自发性脑出血诊断治疗中国多学科专家共识［J］．中华神经外科杂志，2015，31(12)：1189-1194．
［18］曹勇，张谦，于洮，等．中国脑血管病临床管理指南(节选版)：脑出血临床管理［J］．中国卒中杂志，2019，14(8)：809-813．
［19］HEMPHILL J C, GREENBERG S M, ANDERSON C S, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A guideline for healthcare professionals from the American heart association/American stroke association［J］. Stroke, 2015, 46(7): 2032-2060.
［20］中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018［J］.中华神经科杂志,2018,51(9):666-682.
［21］POWERS W J,RABINSTEIN A A,ACKERSON T,et al.2018 Guidelines for the arly management of patients with acute ischemic stroke:A guideline for healthcare professionals from the American heart association/American stroke association［J］. Stroke,2018,49(3):e46-e110.
［22］中华医学会神经病学分会帕金森病及运动障碍学组．中国帕金森病治疗指南(第三版)［J］．中华神经科杂志，2014，47(6)：428-433．
［23］GRIMES D, FITZPATRICK M, GORDON J, et al. Canadian guideline for Parkinson disease［J］. CMAJ, 2019, 191(36): E989-E1004.
［24］余力生,杨仕明.突发性聋诊断和治疗指南(2015)［J］.中华耳鼻咽喉头颈外科杂志,2015,50(6):443-447.
［25］CHANDRASEKHAR S S, TSAI DO B S, SCHWARTZ S R, et al. Clinical practice guideline: Sudden hearing loss (update)［J］. Otolaryngol Head Neck Surg, 2019, 161(1_suppl): S1-S45.
［26］宋丙安．单唾液酸神经节苷脂注射液治疗新生儿缺氧缺血性脑病的疗效及安全性分析［J］．中国实用神经疾病杂志，2017，20(12)：115-116．
［27］江进平，袁天明，莫蔚农．单唾液酸四己糖神经节苷脂钠注射液联合胞二磷胆碱治疗新生儿缺氧缺血性脑病的临床研究［J］．中国临床药理学杂志，2019，35(18)：1992-1995.
［28］王慧媛．我国六城市神经保护剂用药调查与合理性评价［J］．实用药物与临床，2018，21(5)：586-593．
［29］苏云霞，王翔，傅明强，等．神经节苷脂相关吉兰巴雷综合征病例的回顾性分析［J］．药物流行病学杂志，2019，28(10)：667-672．
［30］王素红，张哲成，赵树新．以呼吸肌麻痹起病的神经节苷脂相关性吉兰巴雷综合征2例［J］．中华老年医学杂志，2019，38(1)：84-86．
［31］GOODFELLOW J A, WILLISON H J. Gangliosides and autoimmune peripheral nerve diseases［J］. Prog Mol Biol Transl Sci, 2018, 156:355-382.
［32］张宸，杜昊骐，李铮．脑病相关神经节苷脂研究进展［J］．生物化学与生物物理进展，2019，46(2)：109-120．
［33］张青青，郭孟敏，马文彬，等．外源性神经节苷脂相关性吉兰巴雷综合征的临床特征及肌电图表现(附3例报道)［J］．卒中与神经疾病，2019，26(3)：337-341．
［34］黄雪梅，吴伟，李琴，等．我院单唾液酸四己糖神经节苷脂钠注射液的临床应用监测研究［J］．中国药房，2017，28(29)：4085-4089． |
|
|
|
